Patents by Inventor Jian Ni

Jian Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110165160
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: December 10, 2010
    Publication date: July 7, 2011
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
  • Publication number: 20110151473
    Abstract: Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions.
    Type: Application
    Filed: November 23, 2010
    Publication date: June 23, 2011
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Publication number: 20110135639
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 9, 2011
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
  • Patent number: 7910321
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: March 22, 2011
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen P. Lyn, Mark Hurle
  • Publication number: 20110052590
    Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 3, 2011
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
  • Patent number: 7868570
    Abstract: A controller of a brushless DC electric machine having a rotor and at least a stator winding powered by a driving voltage is provided. The controller includes a position sensor, an advance angle control circuit, and a driving circuit. The position sensor is moved along a reverse rotating direction of the rotor by a prepositioned angle for outputting a position signal. The advance angle control circuit receives the position signal and a driving voltage reproduction signal reproduced from the driving voltage and outputs a commutation control signal lagging the position signal by a first delay time. The driving circuit receives the commutation control signal for outputting a driving signal for controlling a commutation of the brushless DC electric machine.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: January 11, 2011
    Assignee: Delta Electronics, Inc.
    Inventors: Jian Ni, Lijian Wu, Wanbing Jin, Jianping Ying, Shih-Ming Huang, Wen-Shi Huang
  • Publication number: 20110003399
    Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 6, 2011
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: GUO-LIANG YU, JIAN NI, CRAIG A. ROSEN, JUN ZHANG
  • Publication number: 20100330073
    Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 30, 2010
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
  • Patent number: 7824675
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 2, 2010
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Patent number: 7820798
    Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: October 26, 2010
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen, Jun Zhang
  • Publication number: 20100266533
    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
    Type: Application
    Filed: April 30, 2010
    Publication date: October 21, 2010
    Applicant: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
  • Publication number: 20100261207
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 14, 2010
    Applicant: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich, Marc Chevrier
  • Publication number: 20100261194
    Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.
    Type: Application
    Filed: October 30, 2009
    Publication date: October 14, 2010
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Guo-Liang YU, Reinhard EBNER, Jian NI
  • Patent number: 7803615
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: September 28, 2010
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Jeffrey Y. Su, Craig A. Rosen
  • Patent number: 7776560
    Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: August 17, 2010
    Assignee: Human Genome Scienes, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
  • Publication number: 20100196360
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: September 12, 2008
    Publication date: August 5, 2010
    Applicant: Human Genome Sciences, Inc.
    Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
  • Publication number: 20100130417
    Abstract: The present invention discloses transforming growth factor alpha HII polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders, and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptides and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.
    Type: Application
    Filed: June 30, 2009
    Publication date: May 27, 2010
    Inventors: Ying-Fei Wei, Paul S. Meissner, Jian Ni
  • Patent number: 7708996
    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: May 4, 2010
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
  • Patent number: 7709218
    Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides and antibodies that bind TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 4, 2010
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
  • Publication number: 20090311256
    Abstract: The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: November 3, 2008
    Publication date: December 17, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Paul E. Young, Joseph J. Kenny, Henrik S. Olsen, Paul A. Moore, Ying-Fei Wei, John M. Greene, Steven M. Ruben, Ding Liu, Paul R. Crocker